<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2658-6533</journal-id><journal-title-group><journal-title>Research Results in Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2658-6533</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413/2658-6533-2024-10-3-1-0</article-id><article-id pub-id-type="publisher-id">3511</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medicine (miscellaneous)</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;Gerontological features of the effect of the new coronavirus infection on the interleukin profile, inflammation and endogenous intoxication in mature and elderly patients with coronary heart disease&lt;/strong&gt;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;Gerontological features of the effect of the new coronavirus infection on the interleukin profile, inflammation and endogenous intoxication in mature and elderly patients with coronary heart disease&lt;/strong&gt;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Chernov</surname><given-names>Aleksey V.</given-names></name><name xml:lang="en"><surname>Chernov</surname><given-names>Aleksey V.</given-names></name></name-alternatives><email>alex307207@yandex.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Safuanova</surname><given-names>Guzyal Sh.</given-names></name><name xml:lang="en"><surname>Safuanova</surname><given-names>Guzyal Sh.</given-names></name></name-alternatives><email>kaf-kaf-tovpg@bashgmu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Potapov</surname><given-names>Vladimir N.</given-names></name><name xml:lang="en"><surname>Potapov</surname><given-names>Vladimir N.</given-names></name></name-alternatives><email>geriatria_mse@bk.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Bogova</surname><given-names>Olga T.</given-names></name><name xml:lang="en"><surname>Bogova</surname><given-names>Olga T.</given-names></name></name-alternatives><email>geriatria_mse@bk.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Shurgaya</surname><given-names>Maria A.</given-names></name><name xml:lang="en"><surname>Shurgaya</surname><given-names>Maria A.</given-names></name></name-alternatives><email>geriatria_mse@bk.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Chepurnenko</surname><given-names>Svetlana A.</given-names></name><name xml:lang="en"><surname>Chepurnenko</surname><given-names>Svetlana A.</given-names></name></name-alternatives><email>ovp@rostgmu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Antonenkov</surname><given-names>Yuri E.</given-names></name><name xml:lang="en"><surname>Antonenkov</surname><given-names>Yuri E.</given-names></name></name-alternatives><email>ju.antonenkov@vrngmu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Shavkuta</surname><given-names>Galina V.</given-names></name><name xml:lang="en"><surname>Shavkuta</surname><given-names>Galina V.</given-names></name></name-alternatives><email>ovp@rostgmu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Belov</surname><given-names>Vladislav N.</given-names></name><name xml:lang="en"><surname>Belov</surname><given-names>Vladislav N.</given-names></name></name-alternatives><email>ovp.idpo@vrngmu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Shchetinina</surname><given-names>Nadezhda A.</given-names></name><name xml:lang="en"><surname>Shchetinina</surname><given-names>Nadezhda A.</given-names></name></name-alternatives><email>n.a.schetinina@vrngmu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Sudakov</surname><given-names>Oleg V.</given-names></name><name xml:lang="en"><surname>Sudakov</surname><given-names>Oleg V.</given-names></name></name-alternatives><email>o.v.sudakov@vrngmu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Nikulicheva</surname><given-names>Valentina I.</given-names></name><name xml:lang="en"><surname>Nikulicheva</surname><given-names>Valentina I.</given-names></name></name-alternatives><email>kaf-tovpg@bashgmu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Lipatova</surname><given-names>Tatyana E.</given-names></name><name xml:lang="en"><surname>Lipatova</surname><given-names>Tatyana E.</given-names></name></name-alternatives><email>lipatova.t@inbox.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Borshchuk</surname><given-names>Evgeniy L.</given-names></name><name xml:lang="en"><surname>Borshchuk</surname><given-names>Evgeniy L.</given-names></name></name-alternatives><email>k_pubzdrav1@orgma.ru</email></contrib></contrib-group><pub-date pub-type="epub"><year>2024</year></pub-date><volume>10</volume><issue>3</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/medicine/2024/3/Биомедисследования-157-171.pdf" /><abstract xml:lang="ru"><p>Background: Coronary heart disease (CHD) is considered as an independent risk factor for COVID-19, however, the indicators of inflammation and endogenous intoxication in patients with CHD 3-4 weeks after recovery from COVID-19 have not been the subject of scientific research. The aim of the study: Assessment of the gerontological features of the effect of the transferred new coronavirus infection on the indicators of the interleukin profile, inflammation and endogenous intoxication of mature and elderly patients with coronary heart disease in the early stages of recovery. Materials and methods: The study included 58 mature-age patients with coronary heart disease 3-4 weeks after recovery from COVID-19 of moderate severity, who made up the comparison group. The main group of patients was represented by 62 elderly people with coronary heart disease who had suffered a new coronavirus infection and were examined in the same way as the previous group, 3-4 weeks after recovery. The level of C-reactive protein and highly sensitive C-reactive protein in the blood was studied using the Nicomed-reader express analyzer, and antistreptolysin-O was studied using an immunoturbidimetric method on the Cobas 600 analyzer (Switzerland). The blood levels of bilirubin, urea, creatinine and sialic acids were studied using the ROKI biochemical analyzer. The content of systemic cytokines was determined by the Beckton Dickinson FACS Canto 2 (USA). The level of anxiety and depression was studied on the HADS scale. Results: 3-4 weeks after recovery from COVID-19, antistreptolysin-O levels ranged from 120.9 МЕ/ml to 208.1 МЕ/ml. Significant changes among the considered parameters of inflammation and endogenous intoxication in patients with coronary heart disease in old age during recovery from a new coronavirus infection were accompanied by a change in the content of highly sensitive C-reactive protein in peripheral blood. In the early stages of recovery after COVID-19, in elderly patients with coronary heart disease, the concentration of many studied cytokines in blood plasma remained elevated compared with those aged 45-59 years. The excess of reference values in both groups was found for IL-17, TNF-&amp;alpha; and IFN-&amp;alpha;, and among elderly patients &amp;ndash; for IL-3, IL-4, IL-6, IL-7, IL-17. Conclusion: Antistreptolysin-O, highly sensitive C-reactive protein, C-reactive protein can be considered markers of recovery in patients with combined coronary heart disease in the early stages after a new coronavirus infection</p></abstract><trans-abstract xml:lang="en"><p>Background: Coronary heart disease (CHD) is considered as an independent risk factor for COVID-19, however, the indicators of inflammation and endogenous intoxication in patients with CHD 3-4 weeks after recovery from COVID-19 have not been the subject of scientific research. The aim of the study: Assessment of the gerontological features of the effect of the transferred new coronavirus infection on the indicators of the interleukin profile, inflammation and endogenous intoxication of mature and elderly patients with coronary heart disease in the early stages of recovery. Materials and methods: The study included 58 mature-age patients with coronary heart disease 3-4 weeks after recovery from COVID-19 of moderate severity, who made up the comparison group. The main group of patients was represented by 62 elderly people with coronary heart disease who had suffered a new coronavirus infection and were examined in the same way as the previous group, 3-4 weeks after recovery. The level of C-reactive protein and highly sensitive C-reactive protein in the blood was studied using the Nicomed-reader express analyzer, and antistreptolysin-O was studied using an immunoturbidimetric method on the Cobas 600 analyzer (Switzerland). The blood levels of bilirubin, urea, creatinine and sialic acids were studied using the ROKI biochemical analyzer. The content of systemic cytokines was determined by the Beckton Dickinson FACS Canto 2 (USA). The level of anxiety and depression was studied on the HADS scale. Results: 3-4 weeks after recovery from COVID-19, antistreptolysin-O levels ranged from 120.9 МЕ/ml to 208.1 МЕ/ml. Significant changes among the considered parameters of inflammation and endogenous intoxication in patients with coronary heart disease in old age during recovery from a new coronavirus infection were accompanied by a change in the content of highly sensitive C-reactive protein in peripheral blood. In the early stages of recovery after COVID-19, in elderly patients with coronary heart disease, the concentration of many studied cytokines in blood plasma remained elevated compared with those aged 45-59 years. The excess of reference values in both groups was found for IL-17, TNF-&amp;alpha; and IFN-&amp;alpha;, and among elderly patients &amp;ndash; for IL-3, IL-4, IL-6, IL-7, IL-17. Conclusion: Antistreptolysin-O, highly sensitive C-reactive protein, C-reactive protein can be considered markers of recovery in patients with combined coronary heart disease in the early stages after a new coronavirus infection</p></trans-abstract><kwd-group xml:lang="ru"><kwd>new coronavirus infection</kwd><kwd>coronary heart disease</kwd><kwd>inflammation indicators</kwd><kwd>endogenous intoxication</kwd><kwd>interleukins</kwd><kwd>age patients</kwd></kwd-group><kwd-group xml:lang="en"><kwd>new coronavirus infection</kwd><kwd>coronary heart disease</kwd><kwd>inflammation indicators</kwd><kwd>endogenous intoxication</kwd><kwd>interleukins</kwd><kwd>age patients</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nature Medicine. 2021;27(4):601-615. DOI: https://doi.org/10.1038/s41591-021-01283-z</mixed-citation></ref><ref id="B2"><mixed-citation>Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Heart Rhythm. 2020;17(11):1984-1990. DOI: https://doi.org/10.1016/j.hrthm.2020.06.026</mixed-citation></ref><ref id="B3"><mixed-citation>Committee W, Gluckman TJ, Bhave NM, et al. 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2022;79(17):1717-1756. DOI: https://doi.org/10.1016/j.jacc.2022.02.003</mixed-citation></ref><ref id="B4"><mixed-citation>Belyaeva VA. Pathogenetic mechanisms of myocardial damage in COVID-19. Modern Problems of Science and Education. 2021;6:192. Russian. DOI: https://doi.org/10.17513/spno.31299</mixed-citation></ref><ref id="B5"><mixed-citation>Tolpygina SN, Zagrebelny AV, Martsevich SYu. Prognostic value of calcific aortic stenosis in patients of the PROGNOZ IBS registry. Russian Journal of Cardiology. 2022;27(1):4836. Russian. DOI: https://doi.org/10.15829/1560-4071-2022-4836</mixed-citation></ref><ref id="B6"><mixed-citation>Yang L, Wang L, Deng Y, et al. Serum lipids profiling perturbances in patients with ischemic heart disease and ischemic cardiomyopathy. Lipids in Health and Disease. 2020;19(1):89. DOI: https://doi.org/10.1186/s12944-020-01269-9</mixed-citation></ref><ref id="B7"><mixed-citation>Bauersachs R, Zeymer U, Briere JB, et al. Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. Cardiovascular Therapeutics. 2019;2019:8295054. DOI: https://doi.org/10.1155/2019/8295054</mixed-citation></ref><ref id="B8"><mixed-citation>Martsevich SYu, Kutishenko NP, Lukyanov MM, et al. Hospital register of patients with acute cerebrovascular accident (REGION): characteristics of patient and outcomes of hospital treatment. Cardiovascular Therapy and Prevention. 2018;17(6):32-38. Russian. DOI: https://doi.org/10.15829/1728-8800-2018-6-32-38</mixed-citation></ref><ref id="B9"><mixed-citation>Clarke R, Valses-Marquez E, Hill M, et al. Plasma cytokines and risk of coronary heart disease in the PROCARDIS study. Open Heart. 2018;5(1):е000807. DOI: https://doi.org/10.1136/openhrt-2018-000807</mixed-citation></ref><ref id="B10"><mixed-citation>Moccia F, Gerbino A, Lionetti V, et al. COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. Geroscience. 2020;42(4):1021-1049. DOI: https://doi.org/10.1007/s11357-020-00198-w</mixed-citation></ref><ref id="B11"><mixed-citation>Shafeghat M, Aminorroaya A, Rezaei N. How Stable Ischemic Heart Disease Leads to Acute Coronary Syndrome in COVID-19? Acta Biomedica. 2021;92(5):е2021512. DOI: https://doi.org/10.23750/abm.v92i5.12013</mixed-citation></ref><ref id="B12"><mixed-citation>Arsentieva NA, Liubimova NE, Batsunov OK, et al. Plasma cytokines in patients with COVID-19 during acute phase of the disease and following complete recovery. Medical Immunology (Russia). 2021;23(2):311-326. Russian. DOI: https://doi.org/10.15789/1563-0625-PCI-2312</mixed-citation></ref><ref id="B13"><mixed-citation>Laing AG, Lorenc A, Barrio ID, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nature Medicine. 2020;26(10):1623-1635. DOI: https://doi.org/10.1038/s41591-020-1038-6</mixed-citation></ref><ref id="B14"><mixed-citation>Barbarash OL, Karpov YuA. Clinical recommendations &amp;laquo;Stable ischemic heart disease&amp;raquo;. Moscow: Russian Society of Cardiology; 2020. Russian.</mixed-citation></ref><ref id="B15"><mixed-citation>Jurando A, Martin MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. Immunity and Ageing. 2020;17:22. DOI: https://doi.org/10.1186/s12979-020-00194-w</mixed-citation></ref><ref id="B16"><mixed-citation>Deng X, Liu B, Li J, et al. Blood biochemical characteristics of patients with coronavirus disease 2019 (COVID-19): a systemic review and meta-analysis. Clinical Chemistry and Laboratory Medicine. 2020;58(8):1172-1181. DOI: https://doi.org/10.1515/cclm-2020-0338</mixed-citation></ref><ref id="B17"><mixed-citation>Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. Journal of Medical Virology. 2020;92(7):856-862. DOI: https://doi.org/10.1002/jmv.25871</mixed-citation></ref><ref id="B18"><mixed-citation>Wang L. C-reactive protein levels in the early stage of COVID-19. Medecine et Maladies Infectieuses. 2020;50(4):332-334. DOI: https://doi.org/10.1016/j.medmal.2020.03.007</mixed-citation></ref><ref id="B19"><mixed-citation>Chen Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney International. 2020;97(5):829-838. DOI: https://doi.org/10.1016/j.kint.2020.03.005</mixed-citation></ref><ref id="B20"><mixed-citation>Shih LJ, Yang CC, Liao MT, et al. An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications. Virulence. 2023;14(1):2190650. DOI: https://doi.org/10.1080/21505594.2023.2190650</mixed-citation></ref><ref id="B21"><mixed-citation>Li T, Wang D, Wei H, et al. Cytokine storm and translating IL-6 biology into effective treatments for COVID-19. Frontiers in Medicine. 2023;17(6):1080-1095. DOI: https://doi.org/10.1007/s11684-023-1044-4</mixed-citation></ref></ref-list></back></article>